Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Morning versus evening dosing of latanoprost/timolol in elevated intraocular pressure
ChiCTR1900025215Phase 4Not yet recruiting
- Sponsor
- Beijing Tongren Hospital
- Start
- Oct 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, double-blind trial of latanoprost and timolol in open-angle glaucoma (OAG) (2 arms), sponsored by Beijing Tongren Hospital. Primary endpoint: 24-hour intraocular pressure. Planned start Oct 2019; status: not yet recruiting.
02
Drugs
latanoprosttimolol
03
Conditions
open-angle glaucoma (OAG)
Beyond the preview
Go deeper on ChiCTR1900025215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025215.